Publication date: Nov 06, 2019
Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses the health-related quality of life of advanced melanoma survivors treated with ipilimumab (CTLA-4 immune checkpoint inhibition) at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
- Melanoma musings: Dr Ascierto’s trial updates from ESMO
- Melanoma highlights from ESMO 2019
- CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma